In this episode, Dr. Lilja Solnes (Johns Hopkins) and Dr. Martin Pomper (UT Southwestern) explore the current landscape of theranostics in clinical practice, from the early days of targeted radiopharmaceuticals to today’s breakthroughs and future directions. They discuss the success of agents like Lutathera and Pluvicto, the importance of preclinical models, the rise of alpha emitters, and the potential of combination therapies. With candid reflections on what’s working, what’s missing, and how to bridge the gap between research and patient care, this conversation offers deep insights into the evolving role of molecular imaging and therapy.